艾滋病合并马尔尼菲篮状菌及组织胞浆菌2例临床病理分析
Clinical and Pathological Analysis of Two Cases of AIDS Complicated with Talaromyces marneffei and Histoplasma capsulatum
DOI: 10.12677/acm.2025.1582299, PDF, HTML, XML,   
作者: 梁 娟*, 屠云娇, 张 铭, 谭永兴:云南省滇南中心医院(红河州第一人民医院)病理科,云南 蒙自;王巧凤:玉溪市第一人民医院感染科,云南 玉溪
关键词: 艾滋病马尔尼菲篮状菌组织胞浆菌临床病理特征AIDS Talaromyces marneffei Histoplasma capsulatum Clinical and Pathological Characteristics
摘要: 目的:分析艾滋病合并马尔尼菲篮状菌及组织胞浆菌的临床资料、病理表现,探讨其诊断、发病机制和临床治疗方案。方法:回顾性分析2例艾滋病合并马尔尼菲篮状菌及组织胞浆菌的临床病理学特征并复习相关文献。结果:2例患者因不同临床表现入院,实验室检查均提示艾滋病并马尔尼菲篮状菌感染,病理活检提示马尔尼菲篮状菌及组织胞浆菌感染。结论:艾滋病合并马尔尼菲篮状菌及组织胞浆菌感染临床表现复杂多样,诊断和治疗难度较大,及时进行病原学检测及病理学活检,为早期诊断和治疗提供有力支持。
Abstract: Objective: To analyze the clinical data and pathological manifestations of AIDS complicated with Talaromyces marneffei and Histoplasma capsulatum, and to explore its diagnosis, pathogenesis and clinical treatment. Methods: The clinicopathological characteristics of 2 cases of AIDS complicated with Talaromyces marneffei and Histoplasma capsulatum were retrospectively analyzed and relevant literature was reviewed. Results: The 2 patients were admitted to the hospital due to different clinical manifestations. Laboratory tests showed AIDS complicated with Talaromyces marneffei infection, and pathological biopsy showed Talaromyces marneffei and Histoplasma capsulatum infection. Conclusion: The clinical manifestations of AIDS complicated with Talaromyces marneffei and Histoplasma capsulatum infection are complex and diverse, and the diagnosis and treatment are difficult. Timely etiological detection and pathological biopsy provide strong support for early diagnosis and treatment.
文章引用:梁娟, 王巧凤, 屠云娇, 张铭, 谭永兴. 艾滋病合并马尔尼菲篮状菌及组织胞浆菌2例临床病理分析[J]. 临床医学进展, 2025, 15(8): 796-802. https://doi.org/10.12677/acm.2025.1582299

1. 引言

艾滋病(HIV)感染作为一种全球性的公共卫生问题,其并发症的多样性和复杂性一直受到医学界的广泛关注。马尔尼菲篮状菌(Talaromyces marneffei, TM)和组织胞浆菌(Histoplasma capsulatum, HC)是两种常见的机会性治病真菌,尤其容易在免疫功能低下的患者如HIV感染者中引发严重感染。本文报告了2例艾滋病合并马尔尼菲篮状菌及组织胞浆菌感染的病例,并结合相关文献进行复习,以期为临床诊治提供参考。

2. 材料与方法

2.1. 临床资料

患者1,女性,35岁,因口腔颊黏膜溃疡伴皮肤溃疡1月,咽痛4天,于2023年7月31日入住我院感染科。患者1月前无明显诱因出现口腔溃疡,上颚可见出血点,无渗血、血肿及化脓,皮肤四肢散在皮疹,部分已结痂,无脓性分泌物,伴咽痛、咳嗽、咳痰,痰液黄色且不易咳出,间断发热,四肢乏力,劳累,头晕。

体格检查:患者急性面容,表情痛苦。全身皮肤粘膜色泽正常,见皮疹,大小不等,部分已结痂,无脓性分泌物。口腔颊黏膜白斑伴溃疡,上颚可见出血点,全身四肢散在大小不一皮疹,部分已结痂,无脓性分泌物渗出。实验室检查:1) 血生化:白蛋白/球蛋白0.79 (↓),胆汁酸15.5 (μmol/L) (↑),钠离子125.8 (mmol/L) (↓),氯离子88.2 (mmol/L) (↓),钙2.03 (mmol/L) (↓),碳酸氢根30.6 (mmol/L) (↑),乳酸脱氢酶483 (U/L) (↑),肌酸激酶12 (U/L) (↓)。2) 血细胞分析:白细胞计数3.02 × 109/L (↓),中性粒细胞计数2.02 × 109/L (↓),淋巴细胞计数1.02 × 109/L (↓),淋巴细胞比值8.6%。红细胞计数3.37 × 1012/L (↓),中性粒细胞百分数88.20%,血红蛋白浓度78 (g/L) (↓),血小板计数116 × 109/L (↓)。3) C反应蛋白:51.1mg/L。4) 血沉:84 mm/h。5) 免疫学检查:HIV抗体和抗原P24待复检。初步诊断:病毒性感染:HIV抗体阳性待确证;肝功能不全;全血细胞减少;电解质紊乱:低钠低氯低钙血症。入院后完善检查:降钙素原PCT 0.37 ng/ml;血培养:生长马尔尼菲篮状菌,未培养出其他细菌。分子免疫检测:CD4、CD8和CD3细胞绝对计数分别为58、60、156/μL,提示免疫缺陷。

患者2,男性,41岁,无业人员,因长期发热,咳嗽、消瘦及皮疹半月就诊。患者自述HIV感染史多年,未规律服用抗病毒药物。临床表现:患者主要表现为不规则发热、盗汗、食欲减退、进行性消瘦及全身淋巴结肿大。查体示肝脾肿大。全身皮肤见皮疹,大小不等,部分已结痂,无脓性分泌物。实验室检查:1) 血生化:白蛋白/球蛋白0.47 (↓),胆汁酸5.5 (μmol/L) (↑),钠离子132.0 (mmol/L) (↓),氯离子107.6 (mmol/L),钙1.98 (mmol/L) (↓),碳酸氢根32.6 (mmol/L) (↑),乳酸脱氢酶502 (U/L) (↑),肌酸激酶11 (U/L) (↓)。2) 血细胞分析:白细胞计数3.47 × 109/L (↓),中性粒细胞计数2.82 × 109/L (↓),淋巴细胞计数0.25 × 109/L (↓),淋巴细胞比值7.2%。红细胞计数3.89 × 1012/L (↓),中性粒细胞百分数81.20%,血红蛋白浓度81 (g/L) (↓),血小板计数153 × 109/L (↓)。3) 其它:C反应蛋白:75.59 mg/L。血沉:51 mm/h。降钙素原PCT:1.289 ng/ml。EB病毒DNA:4.10E+2 copies/ml。巨细胞病毒DNA:4.18E+2 copies/ml。4) 免疫学检查:丙型肝炎抗体阳性。5) 血培养:生长马尔尼菲篮状菌,未培养出其他细菌。6)分子免疫检测:CD4、CD8和CD3细胞绝对计数分别为21、32、68/μL,提示严重免疫缺陷。影像学检查:胸部CT示双肺弥漫性粟粒性结节,部分区域有融合灶,考虑肺部感染。

2.2. 方法

标本经10%中性福尔马林固定,石蜡包埋,行HE、PAS染色及免疫组化En Vision两步法染色,光镜观察。所用抗体CD68购于福州迈新公司,具体操作步骤按试剂盒说明书进行。

3. 结果

3.1. 镜检

患者1病理活检:肠粘膜活检显示粘膜组织慢性炎并可见较多组织胞浆菌(图1)。患者2骨髓病理活检:骨髓活检显示骨髓增生活跃,各阶段细胞均可见,可见灶状发布巨噬细胞,巨噬细胞胞浆内外可见大量组织胞浆菌及马尼尔菲篮状菌(图2)。

Figure 1. HE Intestinal mucosa chronic inflammation and more histoplasma (yeast-like cells, 2~5 μm in diameter)

1. HE肠粘膜慢性炎并见较多组织胞浆菌(酵母样细胞,直径2~5 μm)

Figure 2. A large number of yeast-like bodies can be seen in the macrophage cytoplasm under the HE microscope, and these bodies can also be scattered outside the cells. Histoplasma presents yeast-like cells with a diameter of 2~5 μm, while Marniflorae appears as branched filamentous bacteria with a diameter of 5~10 μm and is clearly separated

2. HE镜下见巨噬细胞质中可见多量的酵母菌样小体,细胞外亦可见散在的该小体。组织胞浆菌呈现酵母样细胞,直径2~5 μm,马尔尼菲篮状菌则表现为分枝的丝状菌,直径5~10 μm,且有明显的分隔

3.2. 特殊染色及免疫组化

PAS染色真菌染色阳性(图3);CD68巨噬细胞阳性(图4)。

3.3. 治疗及预后

基于患者1临床表现和实验室检查、病理检查,诊断为艾滋病合并马尔尼菲篮状菌及组织胞浆菌感染。治疗方案包括:

抗病毒治疗:根据HIV感染情况,选择合适的抗逆转录病毒药物。

Figure 3. PAS staining fungal staining showed positive yeast-like bodies, mostly round or oval, and typical sausage-like cells and intracellular septals were detected. Broad basal hyphae and spores unique to histoplasma can be seen in some areas

3. PAS染色真菌染色示酵母菌样小体阳性,多为圆形或卵圆形,并检见典型的腊肠状细胞及细胞内横隔。部分区域可见组织胞浆菌特有的宽基底部菌丝和孢子

Figure 4. Immunohistochemical CD68-positive macrophages were significantly increased, indicating an important role for macrophages in clearing infection

4. 免疫组化CD68阳性巨噬细胞显著增多,表明巨噬细胞在清除感染中的重要作用

抗真菌治疗:使用伏立康唑等广谱抗真菌药物针对马尔尼菲篮状菌及组织胞浆菌。支持治疗:纠正电解质紊乱,增强患者免疫力。治疗2周后病情好转。

患者2诊断为艾滋病合并马尼尔菲篮状菌及组织胞浆菌感染;EB病毒及巨细胞病毒感染;慢性丙型肝炎;全血细胞减少;电解质紊乱;低钠低钙血症。患者入院后先给予头孢他啶、莫西沙星等抗生素治疗,但症状改善不明显。后根据病原学结果,改为高效抗逆转录病毒治疗(HAART)联合伊曲康唑及两性霉素B抗真菌治疗。治疗两周后,患者体温恢复正常,咳嗽、咯血症状明显缓解。继续治疗一月后,复查肺部CT示结节明显减少,病情稳定。

4. 文献复习及讨论

马尔尼菲篮状菌(Talaromyces marneffei)是一种温度敏感的双向性真菌,主要流行于亚洲的热带地区,如泰国、印度东北部、越南、老挝、柬埔寨等,我国华南地区尤其是广东、广西多见。马尔尼菲篮状菌通常与皮肤和粘膜感染相关,但在免疫抑制患者中,可能引起更为严重的系统性感染。该真菌在HIV/AIDS患者中并不常见,但一旦发生,可能导致难治性真菌感染。该菌在HIV感染者中发病率较高,随着艾滋病患者的逐渐增多,马尔尼菲篮状菌的感染率也随之增高,目前世界卫生组织(WHO)已经把它作为艾滋病指证性疾病 。在AIDS患者中,马尔尼菲篮状菌在东南亚是位于结核分枝杆菌感染和新型隐球 菌感染之后,排名第三的机会性感染疾病[1]。在泰国AIDS患者中马尔尼菲篮状菌的感染率为30%,中国南方约10%。此外,这些地区每年大约有5万AIDS患者新感染马尔尼菲篮状菌,每年死亡率高达10% [2]。艾滋病合并马尔尼菲篮状菌感染起病隐匿,进展缓慢,临床表现不典型,常表现为发热、皮疹、体重减轻、皮下组织和深部软组织脓肿、肝脾及淋巴结肿大等症状[3],病程早期容易误诊和漏诊,经常误诊为结核、淋巴瘤或组织胞浆菌[4]。在东南亚,每年约有50,000例新发感染和多达5000例死亡病例[5] [6],HIV感染者住院患者中马尔尼菲篮状菌感染率高(可达16.1%),死亡率高于大多数常见HIV相关并发症(AHR = 4.52) [7]-[9]。值得注意的是,有报道称CD4+ T细胞计数降低可导致患者疾病加重,且与死亡率相关[10]-[12]

组织胞浆菌是一种常见于土壤中的真菌,主要通过吸入孢子感染。组织胞浆菌属于高致病性真菌,通常流行于美洲、非洲和亚洲等区域,在我国主要集中流行于云、川、鄂、湘和苏等地。HIV感染者由于免疫功能低下,容易发展为播散性组织胞浆菌病,表现为发热、咳嗽、胸痛、呼吸困难等,有时导致感染性休克及器官功能不全[13],可危及生命[14]-[16],尤其是在CD4+ T细胞计数低于150 cells/μL的患者中[17]

4.1. 发病机制

马尔尼菲篮状菌(TM)和组织胞浆菌(HP)均为条件致病性真菌,主要通过呼吸道感染宿主,然后通过淋巴和血循环播散到肝、脾、淋巴结、皮肤等。人体抵抗TM和HP以细胞免疫为主,其过程主要涉及巨噬细胞对真菌的吞噬和由致敏T细胞所介导的迟发型超敏反应两大部分。TM和HP主要侵犯单核–巨噬细胞网状内皮系统,故而在富含单核–巨噬细胞的组织、器官如淋巴结、肝、脾、肺等发生病变。在免疫功能正常的宿主中,这些真菌通常被固有免疫细胞如巨噬细胞和中性粒细胞识别并清除。然而,在艾滋病等免疫缺陷状态下,不能产生有效Th 1反应以消灭真菌,特异性免疫难以形成,使真菌在网状内皮系统内大量增殖,因而沿着血行广泛播散。且CD4+ T及CD8+ T的消耗可增加消除真菌的困难,真菌得以存活并增殖播散,导致大量器官受累和严重的感染[18] [19]

4.2. 诊断与治疗

诊断主要依赖于临床表现/影像学检查/真菌学检查及病理检查。病原微生物宏基因组检测及G实验等新技术在诊断中发挥了重要作用。治疗方面,通常采用抗真菌药物如伊曲康唑、两性霉素B脂质体等,同时针对HIV感染进行抗病毒治疗。治疗过程中需密切监测病情变化及药物不良反应,及时调整治疗方案。

5. 结论

艾滋病合并马尔尼菲篮状菌及组织胞浆菌感染是一种严重的并发症,临床表现复杂多样,诊断和治疗难度较大。临床医生应提高对这类感染的认识,及时进行病原学检测和免疫状态评估,为早期诊断和治疗提供有力支持。艾滋病合并马尔尼菲篮状菌及组织胞浆菌感染的研究仍处于不断发展之中。未来的研究应着重于提高早期诊断的敏感性和特异性,探索更有效的治疗方案,并加强对该类感染的流行病学监测,以便为临床实践提供更为坚实的依据。

声 明

该病例报道已获得病人的知情同意。

NOTES

*通讯作者。

参考文献

[1] Pruksaphon, K., Intaramat, A., Ratanabanangkoon, K., Nosanchuk, J.D., Vanittanakom, N. and Youngchim, S. (2018) Development and Characterization of an Immunochromatographic Test for the Rapid Diagnosis of Talaromyces (Penicillium) marneffei. PLOS ONE, 13, e0195596.
https://doi.org/10.1371/journal.pone.0195596
[2] Ning, C., Lai, J., Wei, W., Zhou, B., Huang, J., Jiang, J., et al. (2018) Accuracy of Rapid Diagnosis of Talaromyces marneffei: A Systematic Review and Meta-Analysis. PLOS ONE, 13, e0195569.
https://doi.org/10.1371/journal.pone.0195569
[3] Pongpom, M., Vanittanakom, P., Nimmanee, P., Cooper, C.R. and Vanittanakom, N. (2017) Adaptation to Macrophage Killing by Talaromyces marneffei. Future Science OA, 3, FSO215.
https://doi.org/10.4155/fsoa-2017-0032
[4] Wang, Y., Cheng, J., Ding, H., Lin, X., Chen, G., Zhou, M., et al. (2018) Study on the Clinical Features and Prognosis of Penicilliosis marneffei without Human Immunodeficiency Virus Infection. Mycopathologia, 183, 551-558.
https://doi.org/10.1007/s11046-017-0236-3
[5] Bulterys, P.L., Le, T., Quang, V.M., Nelson, K.E. and Lloyd-Smith, J.O. (2013) Environmental Predictors and Incubation Period of Aids-Associated Penicillium marneffei Infection in Ho Chi Minh City, Vietnam. Clinical Infectious Diseases, 56, 1273-1279.
https://doi.org/10.1093/cid/cit058
[6] Armstrong-James, D., Meintjes, G. and Brown, G.D. (2014) A Neglected Epidemic: Fungal Infections in HIV/Aids. Trends in Microbiology, 22, 120-127.
https://doi.org/10.1016/j.tim.2014.01.001
[7] Shi, M., Lin, J., Wei, W., Qin, Y., Meng, S., Chen, X., et al. (2022) Machine Learning-Based In-Hospital Mortality Prediction of HIV/AIDS Patients with Talaromyces marneffei Infection in Guangxi, China. PLOS Neglected Tropical Diseases, 16, e0010388.
https://doi.org/10.1371/journal.pntd.0010388
[8] Meng, S., Tang, Q., Xie, Z., Wu, N., Qin, Y., Chen, R., et al. (2022) Spectrum and Mortality of Opportunistic Infections among HIV/AIDS Patients in Southwestern China. European Journal of Clinical Microbiology & Infectious Diseases, 42, 113-120.
https://doi.org/10.1007/s10096-022-04528-y
[9] Jiang, J., Meng, S., Huang, S., Ruan, Y., Lu, X., Li, J.Z., et al. (2019) Effects of Talaromyces marneffei Infection on Mortality of HIV/AIDS Patients in Southern China: A Retrospective Cohort Study. Clinical Microbiology and Infection, 25, 233-241.
https://doi.org/10.1016/j.cmi.2018.04.018
[10] Pang, W., Shang, P., Li, Q., Xu, J., Bi, L., Zhong, J., et al. (2018) Prevalence of Opportunistic Infections and Causes of Death among Hospitalized HIV-Infected Patients in Sichuan, China. The Tohoku Journal of Experimental Medicine, 244, 231-242.
https://doi.org/10.1620/tjem.244.231
[11] Qiu, Y., Zhang, J., Pan, M., Zeng, W., Tang, S. and Tan, C. (2019) Determinants of Prognosis in Talaromyces marneffei Infections with Respiratory System Lesions. Chinese Medical Journal, 132, 1909-1918.
https://doi.org/10.1097/cm9.0000000000000345
[12] Wang, Y.F., Xu, H.F., Han, Z.G., Zeng, L., Liang, C.Y., Chen, X., et al. (2015) Serological Surveillance for Penicillium Marneffei Infection in HIV-Infected Patients during 2004-2011 in Guangzhou, China. Clinical Microbiology and Infection, 21, 484-489.
https://doi.org/10.1016/j.cmi.2014.12.014
[13] Limper, A.H., Adenis, A., Le, T. and Harrison, T.S. (2017) Fungal Infections in HIV/Aids. The Lancet Infectious Diseases, 17, e334-e343.
https://doi.org/10.1016/s1473-3099(17)30303-1
[14] Adenis, A.A., Valdes, A., Cropet, C., McCotter, O.Z., Derado, G., Couppie, P., et al. (2018) Burden of HIV-Associated Histoplasmosis Compared with Tuberculosis in Latin America: A Modelling Study. The Lancet Infectious Diseases, 18, 1150-1159.
https://doi.org/10.1016/s1473-3099(18)30354-2
[15] Pamnani, R., Rajab, J., Githang’a, J. and Kasmani, R. (2010) Disseminated Histoplasmosis Diagnosed on Bone Marrow Aspirate Cytology: Report of Four Cases. East African Medical Journal, 86, 102-105.
https://doi.org/10.4314/eamj.v86i12.62918
[16] Couppié, P., Herceg, K., Bourne-Watrin, M., Thomas, V., Blanchet, D., Alsibai, K.D., et al. (2019) The Broad Clinical Spectrum of Disseminated Histoplasmosis in HIV-Infected Patients: A 30 Years’ Experience in French Guiana. Journal of Fungi, 5, Article 115.
https://doi.org/10.3390/jof5040115
[17] Wheat, J. (1995) Endemic Mycoses in AIDS: A Clinical Review. Clinical Microbiology Reviews, 8, 146-159.
https://doi.org/10.1128/cmr.8.1.146
[18] Mittal, J., Ponce, M.G., Gendlina, I. and Nosanchuk, J.D. (2018) Histoplasma capsulatum: Mechanisms for Pathogenesis. In: Rodrigues, M., Ed., Fungal Physiology and Immunopathogenesis, Springer, 157-191.
https://doi.org/10.1007/82_2018_114
[19] Allen, H.L. and Deepe, G.S. (2006) B Cells and CD4CD8 T Cells Are Key Regulators of the Severity of Reactivation Histoplasmosis. The Journal of Immunology, 177, 1763-1771.
https://doi.org/10.4049/jimmunol.177.3.1763